Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, and Karyopharm Therapeutics’ selinexor are pursuing initial approvals for the treatment of multiple myeloma. This highlights the fact that untapped clinical and commercial potential remains in multiple myeloma for therapies with improved efficacy, novel mechanisms of actions, and for agents positioned in patient segments that are currently underserved.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.